The FDA has approved Cabometyx for some patients 12 years old and older with previously treated neuroendocrine tumors.

Based on the phase 3 CABINET trial, the FDA approved Cabometyx for some patients with previously treated neuroendocrine ...

The following is a summary of “Impact of functionality and grading on survival in pancreatic neuroendocrine tumor patients ...

The FDA has approved Cabometyx (cabozantinib) for previously treated, unresectable, locally advanced or metastatic, well-differentiated neuroendocrine tumors.

The HealthWell Foundation®, an independent non-profit charitable organization that provides financial assistance for ...

Olivia Williams opened up about her harrowing journey with pancreatic cancer, revealing she experienced years of misdiagnoses, dismissals by doctors.

Olivia Williams, actress known for 'The Crown,' chronicles her challenging journey with pancreatic cancer after years of ...

Olivia Williams, known for her roles in 'The Crown' and 'The Sixth Sense,' has shared her harrowing experience with ...

well-differentiated pancreatic neuroendocrine tumors (pNET) and extrapancreatic NET (epNET). Specifically, the approval is for those with unresectable, locally advanced, or metastatic pNET and ...

Jennifer Chan, MD, MPH, discussed outcomes of treating neuroendocrine tumors (NETs) with cabozantinib depending on whether they were pancreatic NETs or extrapancreatic NETs.

There has been a sharp increase in colorectal and pancreatic cancer rates among Americans under 55 years, despite declines in ...

The approval was based on the results of the phase 3 CABINET study, which compared cabozantinib to a placebo in patients with advanced pancreatic neuroendocrine tumors and advanced extrapancreatic ...